COMMUNIQUÉS West-GlobeNewswire

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
28/03/2026
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab ( [...]
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
28/03/2026
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost clear [...]
Steel Power Male Enhancement Claims Evaluated: Complete SteelPower Performance Report for Men
28/03/2026
A 2026 report outlining Steel Power ingredient research, male enhancement supplement positioning, performance claim context, pricing structure, and what the SteelPower formula label discloses for men Aurora, CO, March [...]
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
28/03/2026
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine , underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositis Brepocitinib 30 mg was [...]
Gelatide Drops Under Investigation: Full Gelatide-1 Consumer Report Reveals Shocking Hidden Risks & Fake Gelatin Trick Recipe
28/03/2026
A 2026 informational consumer evaluation of Gelatide marketing claims, ingredient research context, Akkermansia muciniphila and proprietary blend dosage transparency, the viral gelatin trick weight loss trend, pricing [...]
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
28/03/2026
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, [...]
Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute
28/03/2026
AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute Dans les études de phase 3 COAST 1, COAST 2 et SHORE, l’amlitelimab, administré [...]
SonusZen Claims Evaluated: Testing the Legitimacy of Sonus Zen Formulation for Hearing Support
28/03/2026
A 2026 informational overview of the SonusZen hearing support formulation, Sonus Zen ingredient transparency and B vitamin research context, tinnitus supplement category positioning, auditory health claims, and what [...]
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
28/03/2026
Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, [...]
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
28/03/2026
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms of mild to moderate [...]
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
28/03/2026
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) Quality‑of‑life improvements and itch relief emerged [...]
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
28/03/2026
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology Halle (Saale) / Munich, Germany, March 28 , 2026 - [...]
New SPRAVATO® (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting
28/03/2026
Johnson & Johnson presents findings from the largest European real-world dataset for esketamine nasal spray (NS) which confirm its effectiveness and tolerability in a real-world patient population, which on average [...]
TheraWolf PainBalm and NeuroBalm Claims Evaluated: What Buyers Are Overlooking About Topical Relief Formulas, Ingredients, and Pricing in 2026
28/03/2026
A 2026 consumer overview of TheraWolf PainBalm and NeuroBalm ingredient disclosures, topical magnesium balm research context, botanical pain relief cream claims, nerve comfort formula positioning, pricing structure, and [...]
BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
27/03/2026
Discloses “Going Concern” Explanatory Paragraph in Auditor’s Report NETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the “Company”) today announced that on March 25, 2026, the [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27/03/2026
BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera [...]
Crescent Biopharma Announces Grants of Inducement Awards
27/03/2026
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Cue Biopharma Announces CEO Transition
27/03/2026
Lucinda Warren Appointed Interim President and Chief Executive Officer – Usman Azam Steps Down BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company [...]
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
27/03/2026
Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trial The Company has received feedback from the FDA through Type D interactions, and the Company believes its manufacturing and [...]

Pages